JPWO2021157634A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021157634A5 JPWO2021157634A5 JP2021575844A JP2021575844A JPWO2021157634A5 JP WO2021157634 A5 JPWO2021157634 A5 JP WO2021157634A5 JP 2021575844 A JP2021575844 A JP 2021575844A JP 2021575844 A JP2021575844 A JP 2021575844A JP WO2021157634 A5 JPWO2021157634 A5 JP WO2021157634A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020018249 | 2020-02-05 | ||
| JP2020018249 | 2020-02-05 | ||
| PCT/JP2021/004018 WO2021157634A1 (ja) | 2020-02-05 | 2021-02-04 | タウオパチーおよび認知症関連疾患の判定薬および判定方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021157634A1 JPWO2021157634A1 (https=) | 2021-08-12 |
| JPWO2021157634A5 true JPWO2021157634A5 (https=) | 2024-01-18 |
| JP7752533B2 JP7752533B2 (ja) | 2025-10-10 |
Family
ID=77199622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575844A Active JP7752533B2 (ja) | 2020-02-05 | 2021-02-04 | タウオパチーおよび認知症関連疾患の判定薬および判定方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230349924A1 (https=) |
| EP (1) | EP4101465A4 (https=) |
| JP (1) | JP7752533B2 (https=) |
| KR (1) | KR20220137674A (https=) |
| CN (1) | CN115066610A (https=) |
| AU (1) | AU2021217290A1 (https=) |
| CA (1) | CA3168823A1 (https=) |
| MX (1) | MX2022009607A (https=) |
| TW (1) | TWI853145B (https=) |
| WO (1) | WO2021157634A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| AU2019318888A1 (en) | 2018-08-07 | 2021-03-18 | Sumitomo Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE342509T1 (de) | 2000-01-24 | 2006-11-15 | Innogenetics Nv | Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| ATE514707T1 (de) * | 2002-04-19 | 2011-07-15 | Univ Toronto | Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer |
| AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
| EP1963534A2 (en) * | 2005-12-19 | 2008-09-03 | Genizon Biosciences Inc. | Genemap of the human gene associated with crohn's disease |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| EP2660600B1 (en) * | 2010-12-28 | 2018-08-08 | Sumitomo Dainippon Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
| ME03008B (me) | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| EP2899208A1 (en) | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
| JP7148776B2 (ja) | 2018-08-02 | 2022-10-06 | 国立大学法人山梨大学 | コロニー識別システム、コロニー識別方法およびコロニー識別プログラム |
| AU2019318888A1 (en) * | 2018-08-07 | 2021-03-18 | Sumitomo Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
-
2021
- 2021-02-04 CN CN202180013030.4A patent/CN115066610A/zh active Pending
- 2021-02-04 MX MX2022009607A patent/MX2022009607A/es unknown
- 2021-02-04 AU AU2021217290A patent/AU2021217290A1/en not_active Abandoned
- 2021-02-04 KR KR1020227029345A patent/KR20220137674A/ko not_active Withdrawn
- 2021-02-04 CA CA3168823A patent/CA3168823A1/en active Pending
- 2021-02-04 US US17/794,912 patent/US20230349924A1/en active Pending
- 2021-02-04 EP EP21750738.3A patent/EP4101465A4/en not_active Withdrawn
- 2021-02-04 JP JP2021575844A patent/JP7752533B2/ja active Active
- 2021-02-04 TW TW110104245A patent/TWI853145B/zh active
- 2021-02-04 WO PCT/JP2021/004018 patent/WO2021157634A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021157634A5 (https=) | ||
| JP2022501016A5 (https=) | ||
| Berger et al. | Accumulation of pathological tau species and memory loss in a conditional model of tauopathy | |
| JP2026009931A (ja) | アルツハイマー病の無症状期を診断するためのバイオマーカーおよびその使用 | |
| JPWO2020032027A5 (https=) | ||
| JP2002525114A (ja) | α−シヌクレイン超突然変異体はα−シヌクレイン凝集を促進する | |
| WO2020106598A1 (en) | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies | |
| CN102816764A (zh) | 特异性结合于人心肌肌钙蛋白ⅰ的dna适体 | |
| Wu et al. | Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain | |
| US12306191B2 (en) | Composition for diagnosis of degenerative neurological diseases | |
| WO2015175769A1 (en) | Methods for the detection of amyloid beta oligomers in biological samples | |
| Ward et al. | TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy | |
| WO2011005628A1 (en) | Detection of neurodegenerative disease | |
| NO20050186L (no) | Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser | |
| US20230349924A1 (en) | Determination agent and determination method for tauopathy and dementia-related diseases | |
| JP6883847B2 (ja) | アミロイドβ蛋白並びにタウ蛋白及び／又はリン酸化タウ蛋白の測定方法 | |
| JP2025533674A (ja) | 神経変性疾患の診断におけるディスコイジンドメイン受容体２の使用及び関連するコンピュータ読取可能な媒体 | |
| WO2008042190A2 (en) | Detection of neurodegenerative disease | |
| US20220326259A1 (en) | In vitro diagnostic method for alzheimer's disease based on the albumin redox level in the cerebrospinal fluid | |
| WO2021110105A1 (zh) | 神经调节蛋白1在制备增强trpc6通道活性产品中的应用 | |
| CN1981194A (zh) | 用于分析糖尿病和/或视网膜血管疾病的组合物及其分析方法 | |
| Klunk et al. | P2-031 Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid pet tracer, PIB, in the same manner as human brain amyloid | |
| Kulik et al. | Amyloid‐Beta, Tau, and Microglial Activation in Aged Felid Brains | |
| AU2016235685A1 (en) | Method of diagnosis or treatment of neurological disorders with p75ECD and/or p75 | |
| HK1250395A1 (en) | In vitro diagnostic method for alzheimer's disease based on the albumin redox level in the cerebrospinal fluid |